Phase I clinical trial results indicated that MZE001 could become the first oral therapy option for Pompe disease. Credit: murat photographer / Shutterstock.com.

Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’s MZE001, an oral glycogen synthase 1 (GYS1) inhibitor to treat Pompe disease.

The agreement grants Shionogi the sole rights to MZE001 and related programmes as well as intellectual property globally.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Maze is entitled to receive $150m in upfront payment from Shionogi.

Maze will receive milestone payments contingent on the progress of the development, regulatory approvals and commercial success.

The company will also earn tiered royalties on future net sales of the therapeutic candidate.

See Also:

The 30-day waiting period under the Hart-Scott-Rodino Act in the US has now lapsed, marking the completion of the deal.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MZE001 works by reducing the accumulation of disease-causing glycogen. It hinders GYS1, an enzyme responsible for glycogen synthesis. This inhibition reduces glycogen accumulation in muscles, a key factor in Pompe disease.

Phase I clinical trial results indicated that MZE001 could become the first oral therapy option.

Its potential extends to both a standalone treatment and an adjunctive therapy alongside enzyme replacement, which is currently the standard care.

The US Food and Drug Administration awarded orphan drug designation to MZE001 in 2022.

Shionogi CEO Isao Teshirogi stated:  “This agreement is a strong strategic fit for Shionogi. It will help meaningfully advance our commitment to developing innovative medicines that address unmet medical needs and complement Shionogi’s rapidly expanding pipeline in the focus areas designated in our medium-term business plan STS2030 revision.

“The science behind MZE001 is differentiated and promising, and we look forward to developing the compound as both mono and add-on therapy to enzyme replacement therapies.”

In June 2023, Shionogi entered a definitive agreement to acquire Qpex Biopharma for $140m.